![](https://netrf.org/wp-content/uploads/2024/08/car-t-cell-blog-header-300x199.jpg)
Another CAR T-Cell Clinical Trial Open to Neuroendocrine Cancer Patients
A phase I CAR T-cell clinical trial targeting the molecule IL13Rα2 found on the surface
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
$37.6M
Million in NET research funding
82¢
of every dollar spent in 2022 supported research and education.
11
Countries with ongoing studies
A phase I CAR T-cell clinical trial targeting the molecule IL13Rα2 found on the surface
The Neuroendocrine Tumor Research Foundation (NETRF) extends its deepest gratitude to Ramesh Shivdasani, MD, PhD (Dana-Farber Cancer Institute), George Fisher, MD, PhD (Stanford University), and Daniel Chung, MD (Massachusetts General Hospital) for their exceptional service as members and former Chairs of the NETRF Board of Scientific Advisors (BOSA).
The Neuroendocrine Tumor Research Foundation is excited to share an important update in the field
You can support a brighter future. Make a gift. Host an event. Or volunteer to help us advance our understanding of neuroendocrine tumors.
Learn about neuroendocrine tumor tests, treatments, and research. Find out about educational and inspirational events in the NET community.
NETRF hosts free patient and caregiver neuroendocrine tumor conferences to educate and empower individuals to be part of their care planning and live their best life.